Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands

Vaccine

Volumn 31, Issue 2, 2013, Pages 394-401

  Mollers, M ^a,b   Boot Hein, J ^a   Vriend Henrike, J ^a   King Audrey, J ^a   van den Broek Ingrid, V F ^a   van Bergen Jan, E A M ^a,c,d   Brink Antoinette, A T P ^g   Wolffs Petra, F G ^g   Hoebe Christian, J P A ^f,g   Meijer Chris, J L M ^b   van der Sande Marianne, A B ^a,e   de Melker Hester, E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c National Institute for STI and AIDS Control in the Netherlands   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f South Limburg Public Health Service   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Human Papilloma Virus; Monitoring; Vaccination

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 6; INCIDENCE; MAJOR CLINICAL STUDY; NETHERLANDS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEXUAL BEHAVIOR; WART VIRUS;

ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; INCIDENCE; MALE; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SEXUAL BEHAVIOR; YOUNG ADULT;

EID: 84871389749     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.087     Document Type: Article

References (37)

1. Koutsky L. Epidemiology of genital human papilloma virus infection. Am J Med 1997, 102(5A):3-8.
2. Castle P.E. The evolving definition of carcinogenic human papillomavirus. Infect Agents Cancer 2009, 4:7.
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer Ja Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
4. Ferlay J.S.H., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
5. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective international biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 1995, 87(11):796-802.
6. Coupe V.M., Berkhof J., Bulkmans N.W., Snijders P.J., Meijer C.J. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008, 98(3):646-651.
7. van Bergen J.E.A.M., Sa Fennema J., van den Broek I.V.F., Brouwers E.E.H.G., de Feijter E.M., Pa Hoebe C.J., et al. Rationale, design, and results of the first screening round of a comprehensive, register-based, Chlamydia screening implementation programme in the Netherlands. BMC Infect Dis 2010, 10:293.
8. van den Broek I.V.F., Pa Hoebe C.J., van Bergen J.E.A.M., Brouwers E.E.H.G., de Feijter E.M., Sa Fennema J., et al. Evaluation design of a systematic, selective, internet-based, Chlamydia screening implementation in the Netherlands, 2008-2010: implications of first results for the analysis. BMC Infect Dis 2010, 10:89.
9. van den Broek I.V., van Bergen J.E., Brouwers E.E., Fennema J.S., Gotz H.M., Hoebe C.J., et al. Effectiveness of yearly, register based screening for Chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. BMJ 2012, 345:e4316.
10. van den Broek I.V., Brouwers E.E., Gotz H.M., van Bergen J.E., Op de Coul E.L., Fennema J.S., et al. Systematic selection of screening participants by risk score in a Chlamydia screening programme is feasible and effective. Sex Transm Infect 2012, 88(3):205-211.
11. Niesters H. Quantitation of viral load using real-time amplification techniques. Methods 2001, 25(4):419-429.
12. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol 2009, 10(4):321-322.
13. Kleter B., van Doorn L.J., Schrauwen L., Molijn A., Sastrowijoto S., ter Schegget J., et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999, 37(8):2508-2517.
14. Xue X., Gange S.J., Zhong Y., Burk R.D., Minkoff H., Massad L.S., et al. Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 2010, 19(1):159-169.
15. http://www.sas.com/.
16. Bakker F., de Graaf H., de Haas S. Seksuele gezondheid in Nederland 2009 2009, Rutgers Nisso Groep, Utrecht.
17. Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C., et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005, 191(11):1808-1816.
18. Sellors J.W., Karwalajtys T.L., Kaczorowski J., Mahony J.B., Lytwyn A., Chong S., et al. Incidence: clearance and predictors of human papillomavirus infection in women. CMAJ 2003, 168(4):421-425.
19. Grainge M.J., Seth R., Guo L., Neal K.R., Coupland C., Vryenhoef P., et al. Cervical human papillomavirus screening among older women. Emerg Infect Dis 2005, 11(11):1680-1685.
20. Rijkaart D.C., Bontekoe T.R., Korporaal H., Boon M.E. Alternating high-risk human papillomavirus infection: consequences of progression to cervical intraepithelial neoplasia. Cancer 2006, 108(6):475-479.
21. Maucort-Boulch D., Plummer M., Castle P.E., Demuth F., Safaeian M., Wheeler C.M., et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 2010, 126(3):684-691.
22. Castle P.E., Solomon D., Schiffman M., Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005, 97(14):1066-1071.
23. Moscicki A.H.N., Shiboski S., et al. Risks for incidence human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001, 285:2995-3002.
24. Burchell A.N., Tellier P.-P., Hanley J., Coutlée F., Franco E.L. Influence of partner's infection status on prevalent human papillomavirus among persons with a new sex partner. Sex Transm Dis 2010, 37(1):34-40.
25. Hwang L.Y., Scott M.E., Ma Y., Moscicki A.B. Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. J Reprod Immunol 2011, 88(1):66-71.
26. Giuliano A.R., Harris R., Sedjo R.L., Baldwin S., Roe D., Papenfuss M.R., et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the young women's health study. Baseline 2000, pp. 462-469.
27. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157(3):218-226.
28. Lenselink C.H., Melchers W.J., Quint W.G., Hoebers A.M., Hendriks J.C., Massuger L.F., et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS ONE 2008, 3(11):e3743.
29. Vriend H.J., Boot H.J., van der Sande M.A.B. Type-specific human papillomavirus infections among young heterosexual male and female STI clinic attendees. Sex Transm Dis 2011, 39(1):1.
30. Bruni L., Diaz M., Castellsagué X., Ferrer E., Bosch F.X., de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202(12):1789-1799.
31. Harper D.M., Longacre M.R., Noll W.W., Belloni D.R., Cole B.F. Factors affecting the detection rate of human papillomavirus. Ann Fam Med 2003, 1(4):221-227.
32. Petignat P., Faltin D.L., Bruchim I., Tramer M.R., Franco E.L., Coutlee F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007, 105(2):530-535.
33. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, et al. MAJOR ARTICLE A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. 2005. 46202.
34. Schmeink C.E., Bekkers R.L., Massuger L.F., Melchers W.J. The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. Rev Med Virol 2011, 21(3):139-153.
35. Winer R.L., Feng Q., Hughes J.P., Yu M., Kiviat N.B., O'Reilly S., et al. Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age. Sex Transm Dis 2007, 34(6):371-377.
36. Lazcano-Ponce E., Lorincz A.T., Cruz-Valdez A., Salmeron J., Uribe P., Velasco-Mondragon E., et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011, 378(9806):1868-1873.
37. Snijders P.J., Verhoef V.M., Arbyn M., Ogilvie G., Minozzi S., Banzi R., et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2012, 10.1002/ijc.27790.